Viralgen  

San Sebastian, 
Spain
http://www.viralgen.com

Welcome to ASGCT and Viralgen Vector Core.

At Viralgen, we’re all-in on AAV; in fact, that’s all we do. It’s made us a world leader in rAAV-based gene therapy manufacturing, built on a foundation of unmatched expertise and the world’s largest manufacturing capacity dedicated to AAV—and it’s led to a track record that includes more than 30 AAV serotypes, 1,500+ AAV batches and a 100% success rate for IND/IMPD dossiers. Our Aava™ manufacturing platform is a high-performance, real-world-ready solution that can get high-potential gene therapies to market quickly and efficiently at impressive scale, with better predictability and deeper data. We combine this cutting-edge infrastructure with end-to-end support, fixed-cost packages, all-inclusive pricing models, and total IP freedom to operate.

 Press Releases

• Apertura Gene Therapy and Viralgen Announce Strategic Collaboration to Manu (Mar 19, 2026)

  The strategic manufacturing collaboration is meant to support gene therapy programs using Apertura's TfR1 CapX, a novel AAV capsid that targets human Transferrin Receptor 1 (hTfR1) to cross the blood-brain barrier. Through this collaboration, Apertura licensees can efficiently access the TfR1 CapX plasmid through Viralgen's integrated AAV manufacturing platform by leveraging its technical expertise. This collaboration aims to facilitate the scale-up process and ensure a seamless transition from research to clinical development.

• Viralgen Collaborates with Trogenix to Advance AAV Gene Therapy for Gliobla (Mar 19, 2026)

  As part of this partnership, Viralgen successfully scaled-up and completed in under 12 months a good manufacturing practice (GMP) clinical trial material batch of Trogenix's rAAV gene therapy, TGX-007, accelerating the program's progression toward first-in-human (FIH) clinical trials for glioblastoma, one of the most aggressive and treatment-resistant forms of brain cancer.

• Viralgen Joins Orphan Therapeutics Accelerator Clinical Development Network (Mar 19, 2026)

  As a network partner, Viralgen will provide manufacturing strategy and execution for adeno-associated virus (AAV) gene therapy programs that are being developed under OTXL's distinct model from clinical development through commercialization.